| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10897425 | Cancer Epidemiology | 2015 | 7 Pages |
Abstract
The survival of myeloma is improving progressively in real-life patients, particularly after the widespread use of the novel agents. A comprehensive assessment of comorbidity can help to explain the huge heterogeneity of myeloma outcome. The optimization of current therapeutic resources as well as the incorporation of new drugs will allow further improvement of survival in the coming years.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rafael RÃos-Tamayo, MarÃa José Sánchez, José Manuel Puerta, Juan Sáinz, Daysi-Yoe-Ling Chang, Teresa RodrÃguez, Pilar López, José MarÃa de Pablos, Pilar Navarro, José LuÃs GarcÃa de Veas, Antonio Romero, Pilar Garrido, LucÃa Moratalla,